Yabbr

QBiotics Group, located in Toowong, Queensland, specializes in the discovery and development of novel cell-signaling small molecules aimed at addressing challenging medical conditions, particularly in oncology and wound healing. Their innovative portfolio includes drug candidates like tigilanoltiglate, which is in clinical development for treating soft tissue sarcomas and head and neck cancers, and EBC1013, aimed at chronic and acute wound management. The company leverages a proprietary drug discovery platform known as EcoLogicTM, which harnesses the diverse molecular scaffolds found within Australia's tropical rainforests. With a focus on phenotypic drug screening and utilizing veterinary data for human development, QBiotics is dedicated to delivering significant advancements in medical therapies. Generated from the website